The Asia-Pacific region is the fastest-growing oral GLP-1 market due to the rapidly increasing prevalence of diabetes and obesity, particularly in China, India, and Japan
Considering the beneficial effects of GcgR antagonists on glycaemia [66,67,68], it would seem counterintuitive to employ agonism in a therapy for obesity and, certainly, diabetes
A completely new level of standard in dentistry and it is designed for an immediate loading into the implant
Obesity is not consistently recognized as a medical condition across health insurance plans
This approach is ideal for users seeking a full-service weight loss program with ongoing support from dietitians and doctors
In addition to their blood glucose lowering effect (with a low risk of hypoglycaemia) they also promote weight loss